Huntington's disease: Pathogenesis to animal models

被引:0
作者
Kumar P. [1 ]
Kalonia H. [1 ]
Kumar A. [1 ]
机构
[1] Pharmacology Division, University Institute of Pharmaceutical Science, UGC Centre of Advanced Study, Panjab University
关键词
Excitotoxicity; Gait abnormalities; Huntington's disease; Memory; Oxidative stress;
D O I
10.1016/S1734-1140(10)70238-3
中图分类号
学科分类号
摘要
Huntington's disease (HD) is an inherited genetic disorder, characterized by cognitive dysfunction and abnormal body movements called chorea. George Huntington, an Ohio physician, described the disease precisely in 1872. HD is a dominantly inherited disorder, characterized by progressive neurodegeneration of the striatum but also involves other regions, primarily the cerebral cortex. The mutation responsible for this fatal disease is an abnormally expanded and unstable CAG repeat within the coding region of the gene encoding the huntingtin protein. Various hypotheses have been put forward to explain the pathogenic mechanisms of mutant huntingtin-induced neuronal dysfunction and cell death. None of these hypotheses, however, offers a clear explanation; thus, it re-mains a topic of research interest. HD is considered to be an important disease, embodying many of the major themes in modern neu-roscience, including molecular genetics, selective neuronal vulnerability, excitotoxicity, mitochondrial dysfunction, apoptosis and transcriptional dysregulation. A number of recent reports have concluded that oxidative stress plays a key role in HD pathogenesis. Although there is no specific treatment available to block disease progression, treatments are available to help in controlling the cho-rea symptoms. As animal models are the best tools to evaluate any therapeutic agent, there are also different animal models available, mimicking a few or a larger number of symptoms. Each model has its own advantages and limitations. The present review deals with the pathophysiology and various cascades contributing to HD pathogenesis and progression as well as drug targets, such as dopamin-ergic, -amino butyric acid (GABA)ergic, glutamate adenosine receptor, peptidergic pathways, cannabinoid receptor, and adjuvant therapeutic drug targets such as oxidative stress and mitochondrial dysfunction that can be targeted for future experimental study. The present review also focuses on the animal models (behavioral and genetic) used to unravel pathogenetic mechanisms and the identification of novel drug targets. © 2010 by Institute of Pharmacology Polish Academy of Sciences.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 113 条
[1]  
Acevedo-Torres K., Berrios L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., Ayala-Torres S., Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease, DNA Repair (Amst), 8, pp. 126-136, (2009)
[2]  
Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Et al., Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease, N Engl J Med, 322, pp. 1293-1298, (1990)
[3]  
Andreassen O.A., Ferrante R.J., Hughes D.B., Klivenyi P., Dedeoglu A., Ona V.O., Friedlander R.M., Beal M.F., Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominantnegative mutant, J Neurochem, 75, pp. 847-852, (2000)
[4]  
Ayala A., Venero J.L., Cano J., Machado A., Mitochondrial toxins and neurodegenerative diseases, Front Biosci, 12, pp. 986-1007, (2007)
[5]  
Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W., Chronic quinolinic acid lesions in rats closely resemble Huntington's disease, J Neurosci, 11, pp. 1649-1659, (1991)
[6]  
Beal M.F., Ferrante R.J., Experimental therapeutics in transgenic mouse models of Huntington's disease, Nat Rev Neurosci, 5, pp. 373-384, (2004)
[7]  
Becker L.I., Miguel R.D., Ruzi J.J.F., The endocannabinoid system and Huntington's disease, Curr Drug Targets-CNS & Neurol Disord, 2, pp. 335-347, (2003)
[8]  
Berliocchi L., Bano D., Nicotera P., Ca signals and death programmes in neurons, Philos Trans R Soc Lond B Biol Sci, 360, pp. 2255-2258, (2005)
[9]  
Blum D., Gall D., Cuvelier L., Schiffmann S.N., Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat, Neuroreport, 12, pp. 1769-1772, (2001)
[10]  
Bracci E., Centonze D., Bernardi G., Calabresi P., Dopa mine excites fast-spiking interneurons in the striatum, J Neurophysiol, 87, pp. 2190-2194, (2002)